Who are we?
Davos BioSciences AG (DBS) was founded as a non-profit Biotech SME and spin-off of CK-CARE (Christine Kühne-Center for Allergy Research and Education) and the Kühne-Foundation, a non-profit foundation of the Kühne Family (Kühne and Nagel, Logistics). Davos BioSciences AG is a subsidiary of the Davos Allergy Campus and belongs to the non-profit Kühne-Foundation (www.Kuehne-Stiftung.org).
What is our aim?
Davos BioSciences AG provides a high-quality expertise in biobanking and laboratory services to help pharmaceutical companies in their effort to accelerate and optimize the discovery and development of new therapeutic agents and biomarkers as well as validation of markers and products to meet regulatory requirements. As of today, the main expertise is on atopic dermatitis as well as for other allergic diseases and for other disorders of the immune system. We focus our efforts particularly in the emerging field of precision medicine.
The CK-CARE Registry and Biorepository provides an ideal scientific reference and knowledge background for the activities of Davos BioSciences AG which, in tight collaboration with all members of the CK-CARE consortium and especially with the world-renowned Swiss Institute for Allergy and Asthma Research (SIAF), can benefit from a state-of-the-art technology platform. This enables DBS to rapidly address critical questions in an agile way at any stage, in the preclinical and clinical drug development programs as well as in the development, validation and regulatory qualification of biomarker-based diagnostic tests.